New hope for tough leukemia: DASATINIB trial targets Non-Responders
NCT ID NCT06055621
First seen Mar 15, 2026 · Last updated Jun 16, 2026 · Updated 12 times
Summary
This study tests a drug called DASATINIB in people with acute myeloid leukemia (AML) whose cancer did not improve after standard treatment with VENETOCLAX and AZACITIDINE. About 35 adults who cannot have strong chemotherapy will take DASATINIB for up to 3 months. Doctors will check if the cancer shrinks or goes away using blood tests and bone marrow exams. The goal is to see if DASATINIB can control the leukemia in these hard-to-treat patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.